← Back
Relmada Therapeutics
RLMD · listed on Nasdaq · worth $361.61 million
$3.58
+4.07% on Oct 30
Ten insider buys in the last year, $4.03 million in all. None in the last two weeks.
Green dot = an insider bought◆ = company newsA number = that many on nearby days · click a mark to see who, or read the filing
The shares anyone can buy and sell, leaving out those held by insiders and big long-term owners.
82.6M shares
77% of all shares
Shares borrowed and sold by investors who expect the price to drop.
Company insiders
In the last year, four insiders bought Relmada Therapeutics stock and none sold.
How each buyer's earlier purchases went: the stock about six months later, beside the S&P 500 over the same days. Purchases planned in advance are left out. Past results, not a forecast.
Chief Financial Officer
Maged Shenouda
Bought $1.1M on Nov 5, 2025 — 500,000 shares at $2.20, 63% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Chief Executive Officer
Sergio Traversa
Bought $599.5K on Nov 5, 2025 — 272,500 shares at $2.20, 21% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
CAO and COO
Chuck Ence
Bought $299.2K on Nov 5, 2025 — 136,000 shares at $2.20, 34% of what they now own.
1 of 1 earlier purchase did better than the S&P 500
Big investors
People and funds that reported owning 5% or more of Relmada Therapeutics, newest first.
Filed by someone who owns 5% or more and does not plan to influence the company.Millennium Management LLC4.4%Jun 22
All reports
Every insider trade and SEC report we hold for Relmada Therapeutics.
Newest first
ReportedTradeInsiderOf their holdingShares @ priceValue
Sep 11BoughtMaged ShenoudaSep 11 · Traded Sep 10 · Chief Financial Officer+8.0%79,800 @ $4.25$339.1K
Sep 11BoughtSergio TraversaSep 11 · Traded Sep 10 · Chief Executive Officer+6.7%100,000 @ $4.10$410K
Dec 16, 2025BoughtSergio TraversaDec 16, 2025 · Traded Dec 15, 2025 · Chief Executive Officer+2.1%27,500 @ $4.12$113.3K
8 more with Pro →Analysts, earnings and news
Analysts' price target
$12.40 average
5 analysts
Analysts' opinions, which tend to run optimistic. Not our forecast or advice.
Profit vs what was expected
1 of 3 quarters above
Q2 '26−$0.11 a share+$0.09
Q4 '25−$0.29 a share−$0.15
Q3 '25−$0.30 a share